What is the significance of Britain's approval of Eli Lilly's Foundayo pill?

Britain's medicines regulator, the MHRA, authorised Eli Lilly's Foundayo pill for both weight management and type 2 diabetes — making it the first country in Europe to approve the treatment for both conditions. While approved for use in the UK, the MHRA explicitly stated it is 'not available currently via the NHS' and will instead launch later this month via private prescription only.

How does Foundayo compare to Novo Nordisk's Wegovy pill in terms of dosing convenience?

Foundayo’s chief advantage is convenience: it is a once-daily oral GLP-1 tablet that can be taken without food or water restrictions, whereas the Wegovy pill requires patients to take it on an empty stomach with a small amount of water and then wait 30 minutes before consuming food, beverages, or other medications.

Eli Lilly's weight-loss pill secures first European nod in Britain

Aug 10, 2026

Britain's MHRA approved Eli Lilly's oral weight-loss pill Foundayo for diabetes and weight management, marking the first European authorization. The drug launches privately later this month, intensifying competition with Novo Nordisk's Wegovy in the expanding oral GLP-1 market.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks